Seema Bhat, MD | Authors


Idelalisib: A PI3K Inhibitor on the Horizon

January 09, 2014

Idelalisib is a potent and highly selective PI3K inhibitor that promotes apoptosis in primary cells from patients with different B-cell malignancies. Idelalisib has been shown to affect microenvironmental signaling and cell survival both in vitro and in vivo.